From here
The calendar on the following pages captures the most important U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between July and February 2013. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs.
Well, sure, this information can be interesting for plaining on the market! I think it can be very profitable the strategy of going short for all 28 companies! Of course, some of the drugs will be approved but the magority will fail providing sweet return on the invested money :)
No comments:
Post a Comment